INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David A. Reardon, Steven Brem, Arati Suvas Desai, Stephen Joseph Bagley, Sylvia Christine Kurz, Macarena Ines De La Fuente, Seema Nagpal, Mary Roberta Welch, Adilia Hormigo, Nicholas Carroll, Sarah K Bartra, Patricia Campbell, Kamalnayan Bhatt, Israel Lowy, Jean Boyer, Kimberly Kraynyak, Matthew P Morrow, Trevor McMullan, David B. Weiner, Jeffrey Skolnik
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Pennsylvania, Hospital of the University of Pennsylvania, Abramson Cancer Center, NYU Langone Health, University of Miami, Sylvester Comprehensive Cancer Center, Stanford University, Montefiore Medical Center, Icahn School of Medicine at Mount Sinai, Inovio Pharmaceuticals (United States), Regeneron (United States), The Wistar Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3029211707